Skip to content

Arvinas ARVN Net Change in Cash

Net Change in Cash at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$175.77M-416%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$212.91M-603%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$29.97M+121%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$6.28M+332%
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
-$6.5M-157%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$16.56M+168%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's net change in cash?
Arvinas (ARVN) reported net change in cash of -$55.6M in Q1 2026.
How has Arvinas's net change in cash changed year-over-year?
Arvinas's net change in cash decreased by 185.1% year-over-year, from -$19.5M to -$55.6M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.